Literature DB >> 9818284

Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation.

F Crippa1, E Seregni, R Agresti, C Chiesa, C Pascali, A Bogni, D Decise, V De Sanctis, M Greco, M G Daidone, E Bombardieri.   

Abstract

To investigate the possible role of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) in the prognostic evaluation of primary breast cancer, we studied 86 patients with T1-3 (TNM classification) breast tumours before surgery and compared the tumour FDG uptake, calculated as a standardized uptake value (SUV), with postoperative histopathological findings, steroid hormone receptor status of the tumour, thymidine labelling index (LI) and tissular expression of p53. SUV was significantly higher in infiltrating ductal carcinomas (n = 68; median SUV = 5.6) than in lobular ones (n = 18; median SUV = 3.8), and in grade 3 carcinomas (n = 26; median SUV = 6.2) than in grade 1-2 ones (n = 60; median SUV = 4.9). Moreover, SUV was significantly higher in carcinomas with high levels of p53 (n = 12; median SUV = 9.5) than in those with low levels (n = 48; median SUV = 4.25). By contrast, there was no significant correlation between SUV and the steroid hormone receptor status or LI of tumours. Our data demonstrate that FDG uptake, expressed as SUV, is associated with certain prognostic factors in breast cancer, such as histopathological grading and p53 expression, which can be assessed only by means of postoperative in vitro examinations. Hence, the information provided by FDG-PET is to some extent related to relevant information on tumour biology. The clinical value of these data will have to be confirmed by analysis of the independence of SUV from other prognostic factors by means of a multivariate analysis performed on a larger series of patients with adequate follow-up. If SUV is confirmed as an independent variable, FDG-PET could assume an important role in the determination of appropriate therapeutic strategies for primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818284     DOI: 10.1007/s002590050319

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  36 in total

1.  [Functional and molecular imaging of breast tumors].

Authors:  K Pinker; P Brader; G Karanikas; K El-Rabadi; W Bogner; S Gruber; M Reisegger; S Trattnig; T H Helbich
Journal:  Radiologe       Date:  2010-11       Impact factor: 0.635

2.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

3.  A preliminary study to propose a diagnostic algorithm for PET/CT-detected incidental breast lesions: application of BI-RADS lexicon for US in combination with SUVmax.

Authors:  Mehrdad Bakhshayeshkaram; Yalda Salehi; Mehrshad Abbasi; Razieh Hashemi Beni; Sharareh Seifi; Maryam Hassanzad; Hamid Reza Jamaati; Farahnaz Aghahosseini
Journal:  Eur Radiol       Date:  2019-03-18       Impact factor: 5.315

4.  Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

Authors:  David Groheux; Sylvie Giacchetti; Jean-Luc Moretti; Raphael Porcher; Marc Espié; Jacqueline Lehmann-Che; Anne de Roquancourt; Anne-Sophie Hamy; Caroline Cuvier; Laetitia Vercellino; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-06       Impact factor: 9.236

Review 5.  Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Giorgio Treglia; Emanuela Orlando; Lodovica Dognini; Luca Giovanella; Ramin Sadeghi; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2013-12-13       Impact factor: 2.374

6.  [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.

Authors:  Alina Berriolo-Riedinger; Claude Touzery; Jean-Marc Riedinger; Michel Toubeau; Bruno Coudert; Laurent Arnould; Christophe Boichot; Alexandre Cochet; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

Review 7.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

Review 8.  The role of positron emission tomographic imaging in breast cancer.

Authors:  Michelle D McDonough; Elizabeth R DePeri; Betty A Mincey
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

Review 9.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.

Authors:  K Scheidhauer; C Walter; M D Seemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

Review 10.  FDG-PET for axillary lymph node staging in primary breast cancer.

Authors:  Flavio Crippa; Alberto Gerali; Alessandra Alessi; Roberto Agresti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.